European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer

  • European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Exelixis Inc's (NASDAQ: EXEL) Cabometyx (cabozantinib) in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) for advanced renal cell carcinoma.
  • Exelixis' partner Ipsen Pharma has exclusive rights to commercialize and develop Cabometyx outside of the U.S. and Japan.
  • The positive opinion follows FDA approval for Cabometyx plus Opdivo as a first-line treatment of advanced renal cell carcinoma.
  • Price Action: EXEL shares are 0.05% higher at $21.97, while BMY shares are down 0.2% at $61.9 on the last check Friday.
Loading...
Loading...
BMY Logo
BMYBristol-Myers Squibb Co
$46.950.13%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
47.49
Growth
70.71
Quality
Not Available
Value
29.89
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...